droxidopa has been researched along with Parkinson Disease in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (27.14) | 18.7374 |
| 1990's | 20 (28.57) | 18.2507 |
| 2000's | 3 (4.29) | 29.6817 |
| 2010's | 23 (32.86) | 24.3611 |
| 2020's | 5 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhuri, KR; Podlewska, AM; Rukavina, K; Wamelen, DJV | 1 |
| Duque, KR; Dwivedi, AK; Espay, AJ; Marsili, L; Merola, A; Premoli, I; Sobrero, G; Sturchio, A | 1 |
| Mobarek, SK | 1 |
| Khemani, P; Sin, MK | 1 |
| Kaufmann, H; Palma, JA | 1 |
| Claassen, D; Goodman, BP; Mehdirad, A | 1 |
| Claassen, D; Lew, M | 1 |
| Gupta, F; Karabin, B; Mehdirad, A | 2 |
| Kremens, D; Lew, M | 1 |
| Claassen, D; Goodman, BP; Kremens, D; Lew, M | 1 |
| Claassen, D; Vernino, S | 1 |
| Otero-Losada, M; Pérez-Lloret, S; Quarracino, C; Rascol, O | 1 |
| Hauser, RA; Hewitt, LA; Isaacson, S | 1 |
| Isaacson, SH; Skettini, J | 1 |
| Biaggioni, I; Feirtag, M; Freeman, R; Hewitt, LA; Kaufmann, H; Low, P; Mathias, CJ; Mauney, J; Pedder, S | 1 |
| Hauser, RA; Hewitt, LA; Isaacson, S; Lisk, JP; Rowse, G | 1 |
| Cheng, R; Fan, W; Li, H; Li, Q; Liu, S; Wang, J; Zhang, L; Zhang, Y; Zhao, S; Zheng, J | 1 |
| Aballéa, S; Dorey, J; François, C; Hauser, RA; Hewitt, LA; Kharitonova, E | 1 |
| Abdelazeim, B; Elgebaly, A; Gadelkarim, M; Mattar, O; Negida, A; Salah, R | 1 |
| Isaacson, S; Kalu, U; Rowse, GJ; Vernino, S; White, WB; Ziemann, A | 1 |
| Bordet, R; Defebvre, L; Devos, D | 1 |
| Goldstein, DS; Heredia-Moya, J; Holmes, C; Whittaker, N | 1 |
| Goldstein, DS; Holmes, C; Kopin, IJ; Pechnik, S; Sewell, L | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Antonini, A; Koutsikos, K; Pilleri, M | 1 |
| Krishnamurthi, N; Lieberman, A | 1 |
| Endo, T; Fukada, K; Hamasaki, T; Hazama, T; Sakoda, S; Yokoe, M | 1 |
| Ikemoto, K | 1 |
| Ota, S; Tsuchiya, K | 1 |
| Mathias, CJ | 1 |
| Narabayashi, H | 5 |
| Birkmayer, G; Birkmayer, W; Lechner, H; Riederer, P | 1 |
| Hayashi, A; Kondo, T; Nagatsu, T; Narabayashi, H; Suzuki, T | 1 |
| Kuroda, H; Nukina, I; Ogawa, N; Ota, Z; Yamamoto, M | 1 |
| Kondo, T | 2 |
| Quinn, NP | 1 |
| Hayashi, A; Kishimoto, S; Kondo, T; Narabayashi, H; Sakoda, S; Suzuki, T; Ueji, M | 1 |
| Maruyama, W; Naoi, M; Narabayashi, H | 3 |
| Hayashi, A; Katsube, J; Narabayashi, H; Suzuki, T; Tanaka, C | 1 |
| Lange, KW; Riederer, P; Youdim, MB | 1 |
| Yanagisawa, N | 1 |
| Achiron, A; Goldberg, H; Goren, M; Melamed, E; Sroka, H; Ziv, I; Zoldan, Y | 1 |
| Abe, T; Takahashi, S; Tohgi, H | 1 |
| Kaufmann, H | 1 |
| Nakajima, T | 1 |
| Hayabara, T; Kanzaki, N; Sato, K | 1 |
| Azuma, T; Hiraga, T; Kishimoto, S; Kobayashi, T; Matsubara, T; Mizuno, R; Sakoda, S; Suzuki, T; Tsujino, S; Yoshida, S | 1 |
| Kinoshita, I; Kishikawa, M; Matsuo, H; Mori, M; Nagataki, S; Takashima, H; Tsujihata, M | 1 |
| Igakura, T; Narabayashi, H; Ogawa, T; Yokochi, F | 1 |
| Imai, H; Itoh, T; Narabayashi, H; Yokota, J | 1 |
| Abe, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Kuramoto, S; Noguchi, S; Yoshida, M | 1 |
| Ueno, E | 1 |
| Kagamihara, Y; Nagaoka, M; Nakajima, Y; Tanaka, R | 1 |
| Nagatsu, T | 1 |
| Ogawa, N; Ujike, H; Yamamoto, M | 1 |
| Kondo, T; Nagatsu, T; Narabayashi, H; Yokochi, F | 1 |
| Ujike, H; Yamamoto, M | 1 |
| Kishimoto, S; Sakoda, S; Suzuki, T; Ueji, M | 1 |
| Reches, A | 1 |
| Hayashi, A | 1 |
| Ogawa, N; Takayama, H; Yamamoto, M | 1 |
21 review(s) available for droxidopa and Parkinson Disease
| Article | Year |
|---|---|
Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson's Disease: An Update Since 2017.
Topics: Droxidopa; Humans; Parkinson Disease; Quality of Life; Sleep Initiation and Maintenance Disorders | 2023 |
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.
Topics: Adrenergic alpha-1 Receptor Agonists; Antiparkinson Agents; Clinical Trials as Topic; Droxidopa; Humans; Hypotension, Orthostatic; Midodrine; Outcome Assessment, Health Care; Parkinson Disease; Synucleinopathies | 2020 |
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
Topics: Amyloid Neuropathies, Familial; Blood Pressure; Droxidopa; Humans; Hypotension, Orthostatic; Japan; Neurodegenerative Diseases; Parkinson Disease; Renal Dialysis; Surveys and Questionnaires | 2019 |
Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
Topics: Accidental Falls; Antiparkinson Agents; Blood Pressure; Droxidopa; Humans; Hypotension, Orthostatic; Parkinson Disease; Posture; Time Factors; Treatment Outcome | 2014 |
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Topics: Droxidopa; Humans; Hypotension, Orthostatic; Parkinson Disease; Safety; Treatment Outcome | 2016 |
[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
Topics: Accidental Falls; Antiparkinson Agents; Cholinergic Agents; Dopamine Agents; Droxidopa; Gait Disorders, Neurologic; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Serotonin Receptor Agonists; Synaptic Transmission | 2010 |
[Human striatal D-neurons and their significance].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Droxidopa; Humans; Levodopa; Mental Disorders; Neurons; Norepinephrine; Parkinson Disease; Pluripotent Stem Cells | 2002 |
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System Diseases; Blood Pressure; Clinical Trials, Phase II as Topic; Dopa Decarboxylase; Droxidopa; Enzyme Inhibitors; Europe; Humans; Hypotension, Orthostatic; Multiple System Atrophy; Norepinephrine; Parkinson Disease | 2008 |
[Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
Topics: Adult; Aged; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine beta-Hydroxylase; Droxidopa; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Terminology as Topic | 1983 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline | 1984 |
[Development of L-threo-DOPS, a norepinephrine precursor amino acid].
Topics: Amyloid Neuropathies; Animals; Clinical Trials as Topic; Droxidopa; Female; Humans; Hypotension, Orthostatic; Male; Norepinephrine; Parkinson Disease; Technology, Pharmaceutical | 1994 |
Three types of akinesia in the progressive course of Parkinson's disease.
Topics: Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agents; Droxidopa; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Thalamic Nuclei | 1993 |
Recent advances in pharmacological therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Droxidopa; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; NAD; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
[Recent progress of therapy in patients with Parkinson's disease].
Topics: Brain; Bromocriptine; Delayed-Action Preparations; Droxidopa; Drug Resistance; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine | 1993 |
L-threo-DOPS in advanced parkinsonism.
Topics: Brain; Cyclic AMP; Droxidopa; Homovanillic Acid; Humans; Neurologic Examination; Norepinephrine; Parkinson Disease | 1993 |
Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.
Topics: 5-Hydroxytryptophan; Amino Acids; Animals; Depressive Disorder; Droxidopa; Histidine; Humans; Levodopa; Parkinson Disease | 1996 |
Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine beta-Hydroxylase; Droxidopa; Globus Pallidus; Humans; Levodopa; Norepinephrine; Parkinson Disease; Thalamus | 1999 |
[Recent progress in treatment of Parkinson's disease].
Topics: Droxidopa; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Substantia Nigra; Thalamus | 1990 |
[Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Dopamine Agents; Droxidopa; Humans; Levodopa; Nerve Tissue; Parkinson Disease; Pyridines; Serine | 1988 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodopa; Locus Coeruleus; Myocardium; Norepinephrine; Pargyline; Parkinson Disease; Serine; Stereoisomerism; Tyrosine | 1985 |
[Treatment of orthostatic hypotension by noradrenaline supplement].
Topics: Amyloidosis; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Droxidopa; Humans; Hypotension, Orthostatic; Norepinephrine; Parkinson Disease; Polyneuropathies; Serine | 1985 |
11 trial(s) available for droxidopa and Parkinson Disease
| Article | Year |
|---|---|
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease | 2014 |
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Topics: Aged; Autonomic Agents; Autonomic Nervous System Diseases; Blood Pressure; Dizziness; Double-Blind Method; Droxidopa; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Multiple System Atrophy; Nervous System Diseases; Parkinson Disease; Posture; Pure Autonomic Failure; Time Factors; Treatment Outcome | 2014 |
Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Blood Pressure; Double-Blind Method; Droxidopa; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires; Treatment Outcome | 2015 |
A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Double-Blind Method; Droxidopa; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2015 |
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Blood Pressure; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Droxidopa; Female; Humans; Hypotension, Orthostatic; Male; Markov Chains; Parkinson Disease; Quality-Adjusted Life Years | 2016 |
Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System; Blood Pressure; Droxidopa; Female; Heart Rate; Humans; Hypertension; Hypotension, Orthostatic; Long Term Adverse Effects; Male; Middle Aged; Multiple System Atrophy; Norepinephrine; Parkinson Disease; Prodrugs; Pure Autonomic Failure; Vasoconstrictor Agents; Young Adult | 2016 |
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Carbidopa; Catechols; Double-Blind Method; Droxidopa; Drug Interactions; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Nitriles; Norepinephrine; Parkinson Disease; Prodrugs; Pure Autonomic Failure; Vasoconstriction | 2011 |
L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
Topics: Adult; Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Droxidopa; Drug Therapy, Combination; Gait Ataxia; Humans; Japan; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2013 |
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricles; Combined Modality Therapy; Dopamine; Droxidopa; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Reference Values; Stereotaxic Techniques; Thalamus | 1996 |
L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
Topics: Aged; Apraxias; Clinical Trials as Topic; Droxidopa; Drug Administration Schedule; Female; Gait; Humans; Male; Middle Aged; Parkinson Disease; Serine | 1989 |
L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Topics: Aged; Clinical Trials as Topic; Droxidopa; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Serine | 1985 |
38 other study(ies) available for droxidopa and Parkinson Disease
| Article | Year |
|---|---|
Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.
Topics: Antiparkinson Agents; Droxidopa; Humans; Hypotension, Orthostatic; Parkinson Disease; Reflex | 2022 |
Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report.
Topics: Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Chest Pain; Coronary Artery Disease; Coronary Stenosis; Droxidopa; Dyspnea; Female; Humans; Hypotension, Orthostatic; Parkinson Disease; Percutaneous Coronary Intervention; Posture; Treatment Outcome | 2020 |
Neurogenic Orthostatic Hypotension: An Underrecognized Complication of Parkinson Disease.
Topics: Accidental Falls; Aged; Caregivers; Cognitive Dysfunction; Dizziness; Droxidopa; Humans; Hypotension, Orthostatic; Male; Neuroscience Nursing; Parkinson Disease; Patient Education as Topic; Quality of Life | 2020 |
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, Orthostatic; Midodrine; Parkinson Disease; Supine Position; Treatment Outcome; Vasoconstrictor Agents | 2017 |
Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Antiparkinson Agents; Disability Evaluation; Droxidopa; Drug Interactions; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease; Pure Autonomic Failure | 2017 |
Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
Topics: Aged; Anticoagulants; Antiparkinson Agents; Atrial Fibrillation; Droxidopa; Electrocardiography; Humans; Hypertension; Hypotension, Orthostatic; Male; Parkinson Disease; Patient Education as Topic; Supine Position | 2017 |
Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Diagnosis, Differential; Droxidopa; Humans; Hypotension, Orthostatic; Male; Parkinson Disease; Syncope | 2017 |
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
Topics: Antiparkinson Agents; Droxidopa; Drug Therapy, Combination; Female; Fludrocortisone; Humans; Hypotension, Orthostatic; Middle Aged; Midodrine; Mineralocorticoids; Parkinson Disease; Vasoconstrictor Agents | 2017 |
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Mellitus, Type 2; Droxidopa; Female; Humans; Hypotension, Orthostatic; Midodrine; Parkinson Disease; Polypharmacy; Vasoconstrictor Agents | 2017 |
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
Topics: Accidental Falls; Aged, 80 and over; Antiparkinson Agents; Blood Pressure Monitoring, Ambulatory; Dizziness; Droxidopa; Humans; Hypotension, Orthostatic; Male; Parkinson Disease; Patient Education as Topic; Supine Position | 2017 |
Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Chromatography, Liquid; Droxidopa; Drug Contamination; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease | 2010 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Is there room for new non-dopaminergic treatments in Parkinson's disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Urea | 2013 |
Is there room for non-dopaminergic treatment in Parkinson disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Treatment Outcome; Urea | 2013 |
[Pure akinesia presenting with antecollis].
Topics: Aged; Droxidopa; Dystonia; Female; Humans; Movement Disorders; Parkinson Disease; Supranuclear Palsy, Progressive | 2005 |
DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Dizziness; Droxidopa; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Long-Term Care; Male; Norepinephrine; Parkinson Disease; Serine | 1983 |
DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
Topics: Aged; Antiparkinson Agents; Blood-Brain Barrier; Carboxy-Lyases; Dopamine; Droxidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Serine | 1984 |
Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Topics: Aged; Benserazide; Droxidopa; Gait; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Parkinson Disease; Serine | 1984 |
[D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
Topics: Aged; Droxidopa; Female; Gait; Humans; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Serine; Tremor | 1984 |
Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Topics: Adult; Aged; Carbidopa; Cerebellar Diseases; Droxidopa; Female; Humans; Kinetics; Male; Middle Aged; Olivary Nucleus; Parkinson Disease; Pons; Serine | 1984 |
[The effect of droxidopa on the monoamine metabolsim in the human brain].
Topics: Adult; Biogenic Monoamines; Brain; Droxidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
[Study on the metabolism of droxidopa in humans].
Topics: Brain; Droxidopa; Female; Humans; Male; Middle Aged; Norepinephrine; Parkinson Disease | 1994 |
Primary progressive freezing gait.
Topics: Aged; Diagnosis, Differential; Droxidopa; Female; Gait; Humans; Levodopa; Locomotion; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Posture; Tomography, X-Ray Computed | 1993 |
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Topics: Aged; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Droxidopa; Female; Gait; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 1993 |
Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease?
Topics: Autonomic Nervous System Diseases; Dihydroxyphenylalanine; Droxidopa; Humans; Parkinson Disease | 1996 |
Improved cardiac iodine-123 metaiodobenzylguanidine accumulation after drug therapy in a patient with Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Coronary Circulation; Droxidopa; Female; Follow-Up Studies; Gated Blood-Pool Imaging; Heart; Heart Diseases; Humans; Iodine Radioisotopes; Parkinson Disease; Pergolide; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 1997 |
Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Topics: Aged; Amyloidosis; Benserazide; Blood Platelets; Dose-Response Relationship, Drug; Droxidopa; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Muscular Atrophy; Nervous System Diseases; Neurologic Examination; Norepinephrine; Parkinson Disease; Polyneuropathies; Receptors, Adrenergic, alpha; Yohimbine | 1991 |
Pure akinesia: an atypical manifestation of progressive supranuclear palsy.
Topics: Aged; Brain; Droxidopa; Female; Gait; Gliosis; Humans; Magnetic Resonance Imaging; Middle Aged; Movement Disorders; Neurofibrils; Norepinephrine; Organ Size; Parkinson Disease; Substantia Nigra; Supranuclear Palsy, Progressive | 1991 |
[Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].
Topics: Aged; Aging; Droxidopa; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Serine | 1991 |
[The effect of L-threo-DOPS on P-300 in parkinsonism].
Topics: Aged; Aged, 80 and over; Cognition; Droxidopa; Electrophysiology; Female; Humans; Male; Middle Aged; Parkinson Disease; Serine | 1990 |
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Topics: Carbidopa; Droxidopa; Humans; Levodopa; Middle Aged; Norepinephrine; Parkinson Disease | 1990 |
[Clinical and physiological study of apraxia of gait and frozen gait].
Topics: Aged; Apraxias; Cerebral Infarction; Droxidopa; Female; Gait; Humans; Male; Middle Aged; Parkinson Disease | 1989 |
The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson's disease.
Topics: Adult; Aged; Droxidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscles; Parkinson Disease; Reference Values; Serine; Synapses; Synaptic Transmission | 1987 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques | 1986 |
Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Droxidopa; Drug Therapy, Combination; Glycols; Humans; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Parkinson Disease; Serine | 1986 |
Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Topics: Adult; Aged; Antiparkinson Agents; Droxidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Serine; Shy-Drager Syndrome | 1987 |
Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
Topics: Adult; Aged; Blood Pressure; Cerebrovascular Circulation; Droxidopa; Female; Humans; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Serine | 1988 |
Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
Topics: Atrophy; Brain Diseases; Cerebellum; Droxidopa; Gas Chromatography-Mass Spectrometry; Humans; Hypotension, Orthostatic; Norepinephrine; Olivary Nucleus; Parkinson Disease; Pons; Serine | 1985 |